Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 5, 1997, Pages 337-345

  Phillips, P ^a   Shafran, S ^b   Garber, G ^c   Rotstein, C ^d   Smaill, F ^e   Fong, I ^f   Salit, I ^g   Miller, M ^h   Williams, K ⁱ   Conly, J M ^g,i   Singer, J ^a   Ioannou, S ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d HENDERSON GENERAL HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g TORONTO GENERAL HOSPITAL   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ ROYAL UNIVERSITY HOSPITAL   (Canada)

^j PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNGEMIA; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; CANDIDIASIS; CONFIDENCE INTERVALS; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 8544284077     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01726360     Document Type: Article

References (32)

1. Banerjee SN, Emori TG, Culver DH, Gaynes RR Jarvis WR, Horan T, Edwards JR, Toison J, Henderson T, Martone WJ, and the National Nosocomial Infections Surveillance System: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. American Journal of Medicine 1991, 91, Supplement 3B: 86-89.
2. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clinical Infectious Diseases 1992, 15: 414-421.
3. Komshian SV, Uwaydah AK, Sobel JD, Crane LR: Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Reviews of Infectious Diseases 1989, 11: 379-390.
4. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Archives of Internal Medicine 1988, 148: 2642-2645.
5. Lecciones JA, Lee JW, Navarro EE, Witebsky EG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ: Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clinical Infectious Diseases 1992, 14: 875-883.
6. Horn R, Wong B, Kiehn TE, Armstrong D: Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Reviews of Infectious Diseases 1985, 7: 646-655.
7. Rose HD: Venous catheter-associated candidemia. American Journal of the Medical Sciences 1978, 275: 265-269.
8. Edwards JE Jr, Filler SG: Current strategies for treating invasive candidiasis: emphasis on infections in non-neutropenic patients. Clinical Infectious Diseases 1992, 14, Supplement 1: 106-113.
9. Edwards JE Jr: Should all patients with candidemia be treated with antifungal agents? Clinical Infectious Diseases 1992, 15: 422-423.
10. Goa KL, Barradell LB: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995, 50: 658-690.
11. Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, Potts D, Shelton M, Sugar A: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. American Journal of Medicine 1991, 91: 142-150.
12. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AR Levenstein MJ, Webb CD, for the Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New England Journal of Medicine 1994, 331: 1325-1330.
13. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 325: 1274-1277.
14. Evans TG, Mayer J, Cohen S, Classen D, Carroll K: Fluconazole failure in the treatment of invasive mycoses. Journal of Infectious Diseases 1991, 164: 1232-1235.
15. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrobial Agents and Chemotherapy 1993, 37: 1847-1849.
16. Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW: Fluconazole resistance in Candida glabrata. Lancet 1988, ii: 1310.
17. Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB: Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine 1974, 53: 47-75.
18. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. American Journal of Medicine 1996, 101: 170-176.
19. Galgiani JN: Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies. Reviews of Infectious Diseases 1990, 12, Supplement 3: 272-275.
20. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD, for the NIAID Mycoses Study Group and the Candidemia Study Group: Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40-44.
21. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 1-8.
22. Parkinson T, Falconer DJ, Hitchcock CA: Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrobial Agents and Chemotherapy 1995, 39: 1696-1699.
23. Sanglard D, Kuchler K, Ischer F, Pagani J-L, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy 1995, 39: 2378-2386.
24. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN: Antifungal susceptibility testing. Clinical Microbiology Reviews 1993, 6: 367-381.
25. Graybill JR, Najvar LK, Holmberg JD, Correa A, Luther MF: Fluconazole treatment of Candida albicans infection in mice: Does in vitro susceptibility predict in vivo response? Antimicrobial Agents and Chemotherapy 1995, 39: 2197-2200.
26. Atkinson BA, Bouthet C, Bocanegra R, Correa A, Luther MF, Graybill JR: Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. Journal of Antimicrobial Chemotherapy 1995, 35: 631-640.
27. Price MF, LaRocco MT, Gentry LO: Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrobial Agents and Chemotherapy 1994, 38: 1422-1424.
28. Tiballi RN, Zarins LT, He X, Kauffman CA: Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays. Journal of Clinical Microbiology 1995, 33: 2612-2615.
29. Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL: Therapeutic approaches in patients with candidemia. Archives of Internal Medicine 1995, 155: 2429-2435.
30. Moyer DV, Edwards JE Jr: Candida endophthalmitis and central nervous system infection. In: Bodey GP (ed): Candidiasis: pathogenesis, diagnosis and treatment. Raven Press, New York, 1993, p. 331-355.
31. Filler SG, Crislip MA, Mayer CL, Edwards JE Jr: Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrobial Agents and Chemotherapy 1991, 35: 288-292.
32. Park SS, D'Amico DJ, Paton B, Sullivan Baker A: Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 958-963.